Thermalin Diabetes, LLC
New insulins for recognized needs in $17B market, as leading insulins come off patent. $10M additional on B leads to initial out-licensing in 2015.
Thermalin is developing next-generation insulins to fill gaps in a rapidly growing $17B market. Our new molecules include ultra-concentrated, rapid-acting ($3B addressable), ultra-rapid-acting/fast offset meal-time and pump ($4B), and ultra-heat stable, long- and rapid-acting ($1.8B+) insulins. Existing marketed insulin analogs go off-patent in 2014-16; in preparation, at least 5 major pharmas are actively shopping for superior insulins.